STAT+: In the biotech industry, a most-wanted fugitive was long hiding in plain sight

STAT PlusBiotech In the biotech industry, a most-wanted fugitive was long hiding in plain sight Ronald Fischer used alias, fake CVs more extensively than has been previously reported By Adam FeuersteinJuly 29, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology. Adam Feuerstein[email protected]Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard.

You can reach Adam on Signal at stataf.54. Manage alerts for this article Email this article Share this article When one of Rhode Island’s most-wanted fugitives was discovered last week to have been secretly working under an alias in the biotech industry, the reaction among many was shock. How did he evade scrutiny for two decades?

And how did the companies that hired him — at least one biotech on a full-time basis and at least two large pharmaceutical companies on a contractual basis — not vet him more thoroughly? But to an industry recruiter who spoke with Richard Graydon — the alias used by Ronald Fischer, a former doctor who was convicted of sexual assault and who had spent two decades on the run — it wasn’t altogether surprising. Advertisement Graydon’s stellar academic credentials, board certification, and years of experience leading teams that successfully developed cancer drugs made him an ideal candidate for top jobs at biotech and pharma companies.

Much of his CV appears to have been fabricated, according to a STAT review, but it checked the right boxes. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%!

2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, legal, Pharmaceuticals, STAT+ Submit a correction requestReprints Adam Feuerstein Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard.

You can reach Adam on Signal at stataf.54. Recommended First Opinion July 29, 2026 The VA could help America win the biotechnology race with China Biotech July 28, 2026 STAT Plus: FDA staff reiterate concerns about Replimune skin cancer treatment Advertisement Biotech July 28, 2026 STAT Plus: Preliminary trial results suggest a path to a safer Alzheimer’s treatment Health July 28, 2026 STAT Plus: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD Health Care Inc. Newsletter July 27, 2026 STAT Plus: Pharma’s drug spending deflection Subscriber Picks